Association of Hemopexin in Tear Film and Conjunctival Macrophages With Vernal Keratoconjunctivitis

Jeffrey Chiu Fai Pong, MBChB, MSc, PhD, FRCS(Ed), FRCS(Glas), FCOPhHK, FHKAM(Ophth); Ching Yan Chu, MPhil; Wai Ying Li, MD; Ling Yin Tang, PhD; Lu Li, MD, PhD; Wai Ting Lui, MPhil; Terence Chuen Wai Poon, PhD; Srinivas K. Rao, MD, FRSC(Ed); Dennis Shan Chiu Lam, MBBS, MD, FRCOPhth, FHKAM(Ophth); Chi Chiu Wang, MD, PhD, MRSC; Chi Pui Pang, DPhil

Objective: Vernal keratoconjunctivitis (VKC) is a chronic allergic inflammatory disease with unclear etiology and pathogenesis. We investigated the tear film proteome of patients with VKC to understand the pathologic characteristics of VKC.

Methods: Tear samples were collected from healthy volunteers and patients with VKC. Electrophoresis was performed to display the tear proteomic profiles according to VKC severity. The identities of differentially expressed proteins were analyzed by mass spectrometry and enzyme-linked immunosorbent assay. Immunohistochemistry was performed in VKC conjunctival samples to demonstrate the cellular protein expression. Allergic sensitization was performed in mice to study the pathologic role of these proteins in VKC.

Results: Hemopexin, an inflammatory protein, was elevated in the tear film of patients with VKC. The increased hemopexin concentration in VKC tears was significantly associated with disease severity. Immunohistochemistry showed specific high hemopexin expression in keratinized conjunctival epithelium and necrotic macrophages in patients with VKC. Immunohistochemical examination of normal lacrimal tissues from mice showed that hemopexin was not expressed in any lacrimal apparatus. Under systemic and topical sensitization and challenge using hemopexin in mice, the affected eye had mild to moderate blead discharge, chemosis, and edema with excessive macrophage infiltration and conjunctival necrosis.

Conclusion: An association exists between tear hemopexin and the development and pathologic effects of VKC.

Clinical Relevance: Increased hemopexin may have a role in the development of VKC.

specific IgE for common inhalant antigens such as cedar, cypress pollen, and household dust. However, there was limited correlation of VKC clinical features with these ancillary tests and atopic history.3

Detailed etiologic and pathogenic characteristics of VKC are not well understood. Tearing is one of the most prominent symptoms. Various studies5-10 have demonstrated an abnormal tear film in patients with VKC. During allergic inflammation, conjunctival fibroblasts can release eotaxin into the tear film that has a chemotactic effect on eosinophils, mast cells, and type 2 helper T (TH2) cells readily accumulate in the conjunctiva. Activated eosinophils release major basic proteins, such as eosinophil cationic protein, that can compromise the barrier function of the corneal epithelium and escalate the inflammatory process, resulting in corneal complications.7,8 Mast cells also contribute to the production of these cytotoxic proteins.8 The key causative and upstream molecules involved in the pathologic mechanisms of VKC are yet to be characterized. In a previous study, hemopexin was identified in the tear proteome of patients with VKC. In this study, we further quantified and correlated tear hemopexin concentrations in VKC with clinical severity and attempted to characterize its causative role in the development of VKC in animal models.

### CLINICAL EXAMINATION

According to disease severity, all patients underwent clinical assessment that included a modified scoring system based on their primary symptoms and signs.1 Briefly, for symptoms, a visual analog scale was developed with scores of 0 (none), 1 (mild), 2 (moderate), and 3 (severe) used to assess symptoms of (1) itchiness, (2) discharge, (3) pain, (4) tearing, and (5) photophobia. For clinical signs, each patient was assessed by a qualified ophthalmologist, using the same visual analog scale, for (1) severity of hyperemia, (2) number of Trantas dots, (3) area of punctate keratitis, and (4) size of papillary hypertrophy in each affected eye (Table 1). The sum of the scores of clinical symptoms and signs was calculated, and the overall severity of VKC was classified as mild (≤9), moderate (10-18), and severe (>18).

### TEAR COLLECTION

Tears were collected with a disposable glass capillary micropipette (Drummond Scientific, Broomall, Pennsylvania) designed for tear film collection. Each micropipette, 12 cm long and 1 mm wide, was calibrated with a mark at 10 µL to estimate the volume of tear film collected and was polished at the collection end. During tear collection, the patients with VKC and the control participants were positioned at a slitlamp. The slit beam was narrowed to avoid bright illumination and reflex tearing. With the patient’s lower lid gently everted, the operator gently placed the micropipette laterally at an angle into the inferior fornix cul-de-sac. Contact between the tear meniscus and the micropipette tip facilitated tear collection via capillary action. All tear samples were obtained within a single 5-minute collection, without topical anesthetics. All tear-collection procedures were performed by the same clinical ophthalmologist (J.C.F.P.). Any maneuvers that caused irritation to the conjunctiva during tear collection were recorded, and those specimens were discarded. All collected tears

### METHODS

#### PATIENTS

All patients were referred to and recruited from the territories’ ophthalmology clinics from 2005 to 2008 at the teaching hospitals of The Chinese University of Hong Kong, including Hong Kong Eye Hospital in the Kowloon Central hospital cluster and United Christian Hospital and Tseung Kwan O Hospital in the Kowloon East hospital cluster. On clinical examination, VKC was diagnosed in patients with a history of multiple attacks throughout several years with active symptoms of itching, photophobia, and tearing, together with signs of tarsal or limbal papillae. Patients with seasonal allergic conjunctivitis, atopic keratoconjunctivitis, and giant papillary conjunctivitis were excluded. Patients receiving treatment for atopy were also excluded. The study was conducted according to the guidelines of the Human Ethics Committee of The Chinese University of Hong Kong and the Institutional Review Board of Hospital Authority in Kowloon Central and East hospital clusters and adhered to the Declaration of Helsinki. To collect tear samples, all recruited patients provided informed consent, and parental consent was obtained for individuals younger than 18 years. Healthy people were included in the study as controls. Detailed demographic characteristics, clinical history, disease course, and laboratory investigations were recorded for further analysis. The participants were between 8 and 24 years old, and the male to female ratio was approximately 4:1.

### Table 1. Clinical Scoring System for Patients With Vernal Keratoconjunctivitis

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptom</td>
<td></td>
</tr>
<tr>
<td>Itchiness</td>
<td></td>
</tr>
<tr>
<td>Discharge</td>
<td></td>
</tr>
<tr>
<td>Pain</td>
<td></td>
</tr>
<tr>
<td>Tearing</td>
<td></td>
</tr>
<tr>
<td>Photophobia</td>
<td></td>
</tr>
<tr>
<td>Sign</td>
<td></td>
</tr>
<tr>
<td>Hyperemia</td>
<td></td>
</tr>
<tr>
<td>Trantas dots</td>
<td></td>
</tr>
<tr>
<td>Punctate keratitis</td>
<td></td>
</tr>
<tr>
<td>Papillary hypertrophy</td>
<td></td>
</tr>
<tr>
<td>Total score</td>
<td></td>
</tr>
<tr>
<td>Clinical severity</td>
<td></td>
</tr>
</tbody>
</table>

#### Table 1

<table>
<thead>
<tr>
<th>Score</th>
<th>Symptom</th>
<th>Discharge</th>
<th>Pain</th>
<th>Tearing</th>
<th>Photophobia</th>
<th>Hyperemia</th>
<th>Trantas dots</th>
<th>Punctate keratitis</th>
<th>Papillary hypertrophy</th>
<th>Total score</th>
<th>Clinical severity</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>0</td>
<td>None</td>
<td>None</td>
<td>0</td>
<td>None</td>
</tr>
<tr>
<td>1</td>
<td>Mild</td>
<td>Mild</td>
<td>Mild</td>
<td>Mild</td>
<td>Mild</td>
<td>Mild</td>
<td>1-2</td>
<td>1 Quadrant</td>
<td>Few papillae size &lt;0.2 mm</td>
<td>0</td>
<td>None</td>
</tr>
<tr>
<td>2</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Moderate</td>
<td>3-4</td>
<td>2 Quarters</td>
<td>Papillae size 0.3-1 mm</td>
<td>10-18</td>
<td>Moderate</td>
</tr>
<tr>
<td>3</td>
<td>Severe</td>
<td>Severe</td>
<td>Severe</td>
<td>Severe</td>
<td>Severe</td>
<td>Severe</td>
<td>&gt;4</td>
<td>&gt;3 Quarters</td>
<td>Giant papillae size &gt;1 mm</td>
<td>19-27</td>
<td>Severe</td>
</tr>
</tbody>
</table>

©2011 American Medical Association. All rights reserved.
were immediately transferred to a 0.2-mL centrifuge tube by rapid centrifugation, and supernatants were stored at −80°C until analysis.

**TEAR PROTEOMIC STUDY**

Tear film proteomic profiling was analyzed by 2-dimensional polyacrylamide gel electrophoresis (2D-PAGE; Bio-Rad Laboratories, Hercules, California) to display the differential proteome of all participants and then by matrix-assisted laser desorption ionization–time of flight mass spectrometry to sequence the indexed peptides for protein identification, as previously described. As in the previous study, tear samples from the same group of patients with VKC and control participants were age matched. Tear samples of the patients with VKC were further divided according to clinical severity. Based on the total clinical score, the 2D-PAGE images of mild, moderate, and severe VKC were grouped and compared. Each gel image was acquired by an imaging densitometer (GS-700; Bio-Rad Laboratories) with proprietary software (Quantity One; Bio-Rad Laboratories) and further subjected to imaging analysis by 2-dimensional densitometry software (PDQuest; Bio-Rad Laboratories) to match and analyze the intensities of each protein spot on the gels. The differentially expressed protein spots were excised from the gel, using a gel slicer, and subjected to mass spectrometry with a proteomics analyzer (ABI4700; Applied Biosystems Inc, Carlsbad, California) for protein identification. The classification of VKC clinical severity was masked.

**QUANTIFICATION AND REGRESSION ANALYSIS**

To validate the proteomic results, a commercial sandwich enzyme-linked immunosorbent assay kit (GenWay Biotech, San Diego, California) with specific antibodies against hemopexin was used for quantitative analysis, as reported in a previous study. Concentrations of human hemopexin from the same group of normal and VKC tear samples collected from that cohort study were measured and compared. In the current study, we first performed correlation analysis to determine the relationship between tear hemopexin and clinical severity by Spearman correlation analysis. Stepwise linear regression analyses were then performed, with the hemopexin concentrations in tear samples as independent variables, to determine the relative effect of clinical signs and symptoms of VKC. Continuous variables, such as age, disease duration, and clinical sign and symptom scores, were entered without transformation. Categorical variables, such as sex, positive ancillary test results, atopic history, and disease recurrence, were first transformed into dummy variables. Statistical analyses were performed using SPSS for Windows software, version 13.0 (SPSS, Inc, Chicago, Illinois). A P value <.05 was considered significant.

**IMPRESSION CYTOLOGY AND IMMUNOCYTOCHEMISTRY**

To further characterize hemopexin in pathologic changes associated with VKC, impression cytology on the ocular surface of patients with VKC from a separate cohort was performed and compared with the ocular surface of healthy participants. Informed consent was obtained from all participants. With topical anesthesia, small pieces of sterile cellulose acetate filter paper were applied on the ocular surface so that the most superficial layer of the ocular surface from the temporal, inferior, and nasal regions in each eye was obtained and subjected to standard hematoxylin-eosin staining, to immunocytochemistry using specific antibodies against hemopexin (ABR Affinity BioReagents, Golden, Colorado), as well as to further inflammatory cell characterization.

**ALLERGIC CONJUNCTIVITIS MODELS IN MICE**

To study the expression of hemopexin in the normal eye, healthy adult inbred Institute for Cancer Research mice (Jackson Laboratory, Bar Harbor, Maine) were humanely killed. Whole eyeballs, with the eyelids and lacrimal apparatus structures, were excised, fixed in 4% paraformaldehyde and embedded in paraffin wax for sagittal sectioning and immunohistochemical staining for hemopexin.

To further investigate the pathologic roles of hemopexin in VKC, an allergic conjunctivitis mouse model, according to the protocol of Nakamura et al, was used to study the anatomic and cellular responses on the ocular surface. Animal ethics approval was obtained from The Chinese University of Hong Kong, and all animal care was carried out according to the institutional guidelines. Briefly, 8-week-old Institute for Cancer Research mice were randomized and systemically sensitized by an intraperitoneal injection of 0.1 mL of 10-µg/mL recombinant hemopexin protein (R&D Systems, Minneapolis, Minnesota) or vehicle (sterile phosphate-buffered saline solution) on alternate days for 2 weeks (day 0 to day 14). Short ragweed (SRW) pollen extracts (Greer Laboratories, Inc, Lenoir, North Carolina), at 100 µg/mL in 0.1 mL, were used for comparison because SRW has been used for genetic and immunologic studies in an allergic conjunctivitis model. The sensitization period was followed by administration of high-titer topical eye-drops of recombinant hemopexin protein (100 µg/mL in 0.02 mL) or SRW (400 µg/mL in 0.02 mL) to the left eye once daily for a week (day 13 to day 21) until the appearance of mild or moderate clinical symptoms. The right eye was administered normal saline as a control in the same animal. To avoid crossover, the mice were maintained in a lateral position during topical administration, and the volume was controlled to 5 µL in each drop 4 times during 5 minutes. Drop administration was completed in one eye and then in the other eye 30 minutes later. The experimental challenge of higher titers of hemopexin or SRW was performed on day 24. All animals were assessed by masked observers. Both the behavior of mice in the cage and specific clinical symptoms in each eye, such as tearing and discharge, conjunctival edema and redness, and lid edema and redness, were assessed. To evaluate the inflammatory cell infiltration in the conjunctiva during the late-phase reaction, whole eye tissues were excised 24 hours after the final challenge (day 25), fixed in 4% paraformaldehyde and embedded in paraffin wax for sagittal sectioning, standard histologic staining, and immunohistochemical analysis, as described in the “Impression Cytology and Immunocytochemistry” subsection. Particular attention was paid to anatomic changes in the cornea, conjunctival complications, and eyelid inflammation.

**RESULTS**

**HEMEPOXIN LEVEL IN VKC TEAR PROTEOME AND ITS ASSOCIATION WITH VKC CLINICAL SEVERITY**

As previously reported, 14 tear samples from 7 patients with VKC and 7 healthy controls were collected for initial tear proteomic analyses. According to the total clinical sign and symptom score, VKC tear samples were classified as severe (n=2), moderate (n=3), and mild (n=2) and then were matched with control tear samples by age (±1 year) (Table 2). Figure 1 shows the representa-


©2011 American Medical Association. All rights reserved.

Downloaded From: https://jamanetwork.com/ on 10/23/2023
tive protein separation of tear samples by 2D-PAGE from patients with various clinical severities of VKC (Figure 1A). Although there was some variation in samples of mild VKC, the overall protein spot intensity of ID 3743 in 2D-PAGE gel was significantly higher in VKC tear samples than in control samples (Figure 1B and Table 2). Subsequent protein identification by matrix-assisted laser desorption ionization–time of flight confirmed that hemopexin was differentially expressed between VKC tear samples and control tear samples.

Human hemopexin enzyme-linked immunosorbent assay quantitative kit (GenWay) was used for validation and quantification in tear samples from patients with VKC and control participants recruited in another cohort study. A total of 29 tear samples from 14 mild, 12 moderate, and 3 severe VKC cases were collected. Eight normal tear samples from individuals with no ocular diseases were collected as controls (Table 3). A scatterplot showed a strong correlation between the hemopexin concentrations in tear samples and clinical severity with a regression coefficient $r$ of 0.85 ($P<.001$), suggesting a significant association of tear hemopexin concentrations with VKC clinical severity (Figure 2). Hemopexin concentrations increased from 21.9-fold to 105.5-fold for mild to severe VKC. In regression analysis, tear hemopexin concentrations were a significant determinant of total clinical sign and symptom scores ($P<.001$) but were independent of patient age, sex, disease duration, ancillary test results, atopic history, and disease recurrence (all $P>.05$). The adjusted $R^2$ value for significant variables was 0.48. In an additional stepwise multiple regression analysis, only clinical sign scores accounted for significant variance in tear hemopexin, with an adjusted $R^2$ of 0.26, suggesting a relationship with pathologic changes in the ocular surface.

HEMOPEXIN EXPRESSION IN VKC CONJUNCTIVAL EPITHELIUM AND MACROPHAGES

After initial tear proteomic analysis and subsequent enzyme-linked immunosorbent assay validation, we conducted impression cytologic studies in patients with VKC. Six previously untreated participants from other experiments were recruited, since treatment had been started in most patients with VKC enrolled in other experiments. The eye surface showed an increase in dekeratinized conjunctival epithelial cells and inflammatory cells, including neutrophils, eosinophils, and macrophages, in patients with VKC but not in control participants (Figure 3). Immunocytochemical analysis of impression cytology showed high immunoreactive hemopexin in the dekeratinized conjunctival epithelial cells and necrotic macrophages, confirmed by specific macrophage immunostaining by CD163 antibody (Santa Cruz Biotechnology, Santa Cruz, California), but not in neutrophils or eosinophils. This observation supported the specific hemopexin expression in these cell types in VKC.

<table>
<thead>
<tr>
<th>Pair</th>
<th>Severity</th>
<th>Age, y/Sex</th>
<th>Total Score</th>
<th>HPX Protein Spot Intensity</th>
<th>Matched Healthy Controls</th>
<th>Age, y/Sex</th>
<th>Total Score</th>
<th>HPX Protein Spot Intensity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Mild</td>
<td>9/M</td>
<td>3</td>
<td>19.8</td>
<td>8/F</td>
<td>0</td>
<td>0.0</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Mild</td>
<td>16/M</td>
<td>3</td>
<td>23.7</td>
<td>17/M</td>
<td>0</td>
<td>3.4</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Moderate</td>
<td>13/M</td>
<td>11</td>
<td>109.3</td>
<td>12/M</td>
<td>0</td>
<td>13.5</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Moderate</td>
<td>10/F</td>
<td>10</td>
<td>119.7</td>
<td>11/F</td>
<td>0</td>
<td>28.9</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Moderate</td>
<td>19/M</td>
<td>12</td>
<td>134.8</td>
<td>21/F</td>
<td>0</td>
<td>24.4</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Severe</td>
<td>11/M</td>
<td>19</td>
<td>293.8</td>
<td>11/M</td>
<td>0</td>
<td>0.0</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Severe</td>
<td>24/F</td>
<td>21</td>
<td>1426.9</td>
<td>21/F</td>
<td>0</td>
<td>0.0</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: HPX, hemopexin; VKC, vernal keratoconjunctivitis.

$^a$There were no significant differences between the patients with VKC and the matched healthy controls with regard to mean (SD) age (14.57 [5.44] vs 14.43 [5.22] years; $P=.96$, Mann-Whitney test) or sex (ratio of males to females, 5:2 vs 3:4; $P=.59$, Fisher exact test). We found a significant difference between groups with regard to HPX protein spot intensity (patients with VKC vs matched healthy controls, 304.00 [50.32] vs 10.03 [1.24]; $P=.02$, Mann-Whitney test).
Figure 1. Comparative tear proteome of normal control and vernal keratoconjunctivitis (VKC). A, Representative 2-dimensional polyacrylamide gel electrophoresis images of control and mild, moderate, and severe VKC. The locations of the hemopexin protein spots (ID 3743) are indicated (arrowheads). The observed isoelectric points and molecular weight values are 2.8 and 58 kDa, respectively. B, Hemopexin protein spots in the individual 2-dimensional polyacrylamide gel electrophoresis images from 7 paired tear samples. Yellow squares indicate the selected area for protein spot intensity quantification.

(Figure 5A). The control eyes in both the hemopexin and SRW groups had no such morphologic changes. On detailed microscopic examination, severe conjunctival inflammation, corneal punctuate epitheliopathy, shield ulcer, stromal edema, and neutrophil and eosinophil infiltrations were observed in all animals of the hemopexin group, but not in animals of the SRW group. Notably, a predominance of necrotic conjunctival epithelial cells and macrophages was found only in the hemopexin-sensitized and challenged eyes (Figure 5B).
Hemopexin levels are elevated in VKC tear samples. This trend could be the result of a macrophage inflammatory process or hemopexin secretion in association with the allergic response and pathologic ocular surface changes of VKC. Hemopexin belongs to the family of acute-phase proteins and is secreted after an inflammatory event. Similar to proteins such as haptoglobin and C-reactive protein, hemopexin is a class I acute phase protein gene that requires interleukin (IL) 1 and IL-6 for maximal induction. Hemopexin is a type II acute-phase reactant glycoprotein that serves as a scavenger and transporter of toxic plasma heme to protect against oxidative damage resulting from the catalytic activity of hemolysis or rhabdomyolysis. It also has been reported to inhibit necrosis and adhesion of polymorphonuclear leukocytes and to play a key role in the homeostasis of nitrous oxide. Biochemical studies have demonstrated the antioxidant properties of hemopexin. Heme and hemin can stimulate lipid peroxidation by decomposing lipid peroxides, which occurs when a lipid molecule is attacked by a reactive oxygen species and undergoes oxidation, resulting in cell damage. In the presence of hemopexin, heme-stimulated lipid peroxidation is inhibited.

Hemopexin is mainly expressed in the liver and has a high infinity for heme with an equimolar ratio. Hemopexin belongs to the family of acute-phase proteins and is secreted after an inflammatory event. Similar to proteins such as haptoglobin and C-reactive protein, hemopexin is a class I acute phase protein gene that requires interleukin (IL) 1 and IL-6 for maximal induction. Hemopexin is a type II acute-phase reactant glycoprotein that serves as a scavenger and transporter of toxic plasma heme to protect against oxidative damage resulting from the catalytic activity of hemolysis or rhabdomyolysis. It also has been reported to inhibit necrosis and adhesion of polymorphonuclear leukocytes and to play a key role in the homeostasis of nitrous oxide. Biochemical studies have demonstrated the antioxidant properties of hemopexin. Heme and hemin can stimulate lipid peroxidation by decomposing lipid peroxides, which occurs when a lipid molecule is attacked by a reactive oxygen species and undergoes oxidation, resulting in cell damage. In the presence of hemopexin, heme-stimulated lipid peroxidation is inhibited.

Hemopexin is mainly expressed in the liver and has a high infinity for heme with an equimolar ratio. After heme binding, hemopexin undergoes a conformational change for interaction with a specific receptor, expressed mainly on the hepatocyte membrane, and is then internalized for further catabolism in the cytosol. In addition to the liver, hemopexin is expressed in the central nervous system, retina, and peripheral nerves. Studies of mRNA have revealed that apo-hemopexin is found in the retina and is likely synthesized by neural retinal cells, including ganglion cells and photoreceptors. Because the blood-retinal barrier precludes the release of the heme-hemopexin complex, it is possible that the neuoretina has its own degradation mechanisms. Hemopexin can also inhibit the toxic effects of heme on retinal epithelial cells.
postulated to serve a protective function in the neuro-retina. Hemopexin can bind and transport extracellular heme released by hemolysis, inflammation, and trauma. The heme-hemopexin complex can also bind nitric acid. Production of hemopexin locally maintains the integrity of the blood-retinal barrier against radical oxygen intermediates.

To our knowledge, there have been no studies demonstrating the presence of hemopexin in tears. We have shown for the first time a correlation between the elevation of hemopexin concentrations in tears and the clinical severity of VKC. Linear regression analysis demonstrated the significant correlation shown in Figure 2. With increased clinical severity, there were more corneal complications and more pathologic changes on the conjunctiva and limbus. Elevated concentrations of hemopexin in tears could be attributed to further breakdown of the ocular surface, increased vascular permeability from the circulation, or both of these mechanisms. The correlation of hemopexin with clinical severity could be a potential biomarker for disease diagnosis and monitoring.

Tears are produced from various sources, such as acinar cells of lacrimal glands, goblet cells, and meibomian glands. Further localization of the source of hemopexin led us to conduct immunohistochemical studies in animals. The negative results of hemopexin staining in lacrimal glands, meibomian glands, and goblet cells indicate that hemopexin may not be released from tear-secreting structures. The positive results of macrophage hemopexin immunostaining in the connective tissue of eyelids in healthy animals (Figure 3H) and the ocular surface of patients with VKC (Figure 4) suggest a possible systemic source of hemopexin. Similarly, various antimicrobial tear proteins are promptly delivered by circulating neutrophils to sites of microbial invasion.24 In particular, lactoferrin is an iron-scavenging transferrin protein that has antimicrobial activity via its high affinity with iron and can modulate the ability and aggregation of bacteria and inhibit both bacteria and viruses. The recruitment and release of hemopexin in the tear film from circulating neutrophils require further characterization.

Figure 4. Hemopexin in impression cytology in patients with vernal keratoconjunctivitis (VKC). High hemopexin immunoreactivity was detected in conjunctival epithelial cells and macrophages (red arrowheads) (B and D), but not in neutrophils (black arrowhead) (D), in VKC samples (original magnification ×100). The inset shows positive staining of CD163 antibody specific for macrophages (original magnification ×100). No hemopexin immunoreactivity was detected in control samples (A and C).
We have also used impression cytology to demonstrate the presence of hemopexin in immunocytochemical studies on the conjunctiva of patients with VKC. Hemopexin is found in the cytoplasm of conjunctival epithelial cells and in macrophages in impression cytology samples (Figure 4). Furthermore, animal models of chronic allergic keratoconjunctivitis confirmed the pathologic role of hemopexin in VKC, as hemopexin can induce ocular pathologic changes in patients with VKC and mediate excessive macrophage infiltration and necrosis in affected conjunctiva (Figure 5). In our challenge test in mice, hemopexin reproduced similar conjunctival changes as in humans, but such pathologic changes were not observed in SRW-induced allergic keratoconjunctivitis. To test the specificity of hemopexin in VKC, tear hemopexin concentrations in other types of conjunctivitis can be measured in future studies. At this stage, it is still unclear whether increased hemopexin and macrophages in conjunctival epithelia are a primary or secondary result of the disease. Further detailed experiments, including cellular and molecular studies, are necessary to determine the source of hemopexin and how it interacts with other inflammatory proteins. Although the late-phase reactions of hemopexin on the ocular surface of animals may not reflect the local immune reaction of hemopexin in humans with VKC, the hemopexin sensitization study confirmed its direct allergic effects on the ocular surface and furthered our understanding of the pathogenesis and corneal complications of VKC.

Most tissues need protection from iron- and heme-mediated oxidative damage. The liver, for example, expresses both transferrin and hemopexin as extracellular protection against toxic radical oxygen intermediate-inducing effects of iron and heme, respectively. With the presence of the blood-retinal barrier, these protective proteins may be too slow and the levels may be too low to prevent damage. Thus, local production of hemopexin and haptoglobin by the photoreceptors and ganglion cells is necessary. Baumann and Gauldie suggested that production of such acute-phase proteins is mediated via IL-1 and IL-6 in rat hepatocytes. On the ocular surface, a similar mechanism is possible for protection against iron- and heme-mediated toxic effects. There could be local production and an increase from the circulation during inflammation. Increases of IL-1, IL-4, and IL-5 in tear film have been found in other studies and in our current tear proteomic profiling; IL-4 was also increased in tears in VKC. The cytokine IL-4 induces differentiation of naïve helper T cells to Th2 cells. Upon activation by IL-4, Th2 cells subsequently produce additional IL-4. Understanding how hemopexin interacts with these interleukins at the ocular surface is important for understanding the pathogenesis of VKC.

Submitted for Publication: August 3, 2010; final revision received October 10, 2010; accepted October 13, 2010.

Correspondence: Chi Pui Pang, DPhil, Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, 3/F Hong Kong Eye Hospital, 147K Argyle St, Kowloon, Hong Kong (cppang@cuhk.edu.hk) and Chi Chiu Wang, MD, PhD, MRSC, Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, 1/F Prince of Wales Hospital, Shatin, New Territories, Hong Kong (ccwang@cuhk.edu.hk).

Financial Disclosure: None reported

Additional Contributions: Kent Tsang, PhD, from the Bone Marrow Transfusion Unit, Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, Shatin, Hong Kong, provided expert examination and advice on impression cytology and additional hematologic characterization.

REFERENCES


Visit www.archophthalmol.com. You can send an e-mail to a friend that includes a link to an article and a note if you wish. Links will go to short versions of articles whenever possible.